According to a new report, published by KBV research, The Global Antimicrobial Resistance Diagnostics Market size is expected to reach $5.7 billion by 2028, rising at a market growth of 6.1% CAGR during the forecast period.
The NGS market is showcasing a CAGR of 6.8% during (2022 - 2028). The massively parallel sequencing methodology known as "next-generation sequencing" (NGS) provides extremely high scalability, throughput, and speed. Using this method, the nucleotide sequence of whole genomes or particular DNA or RNA segments can be ascertained.
The Hospitals market is leading the segment in the Global Antimicrobial Resistance Diagnostics Market by End-user in 2021, achieving a market value of $2.8 billion by 2028. This is explained by the rise in hospital-acquired infections, a spike in hospitalizations brought on by the high prevalence of AMR infections, lengthened hospital stays, expanding access to novel diagnostic tools, affordability, and better healthcare coverage.
The Clostridium Difficile (CD) market is exhibiting a CAGR of 6.3% during (2022 - 2028). The high overall incidence and growing capacity for drug resistance against numerous medications are accountable for the rising percentage. Several factors contribute to the development of antibiotic resistance in C. difficile strains, including altered protein expression, the spread of mobile genetic components, iron metabolism, gene mutations, DNA repair, and biofilm formation.
The North America market dominated the Global Antimicrobial Resistance Diagnostics Market by Region in 2021; thereby, achieving a market value of $2.1 billion by 2028. The Europe market is anticipated to grow at a CAGR of 5.4% during (2022 - 2028). Additionally, The Asia Pacific would witness a CAGR of 7.1% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/antimicrobial-resistance-diagnostics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, BioMérieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Danaher Corporation, Accelerate Diagnostics, Inc., Hologic, Inc., Visby Medical, Inc., Vela Diagnostics Pte. Ltd. (Luye Medical Group Co., Ltd) and Molsid S.A.S.
By Technology
By End User
By Pathogen
Companies Profiled
Unique Offerings 
